291 related articles for article (PubMed ID: 31255589)
1. A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study.
Stefanutti C; Pang J; Di Giacomo S; Wu X; Wang X; Morozzi C; Watts GF; Lin J
J Clin Lipidol; 2019; 13(4):608-617. PubMed ID: 31255589
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.
Reijman MD; Tromp TR; Hutten BA; Hovingh GK; Blom DJ; Catapano AL; Cuchel M; Dann EJ; Gallo A; Hudgins LC; Raal FJ; Ray KK; Sadiq F; Soran H; Groothoff JW; Wiegman A; Kusters DM; ;
Lancet Child Adolesc Health; 2024 Jul; 8(7):491-499. PubMed ID: 38759658
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
Bruckert E; Kalmykova O; Bittar R; Carreau V; Béliard S; Saheb S; Rosenbaum D; Bonnefont-Rousselot D; Thomas D; Emery C; Khoshnood B; Carrié A
Atherosclerosis; 2017 Feb; 257():130-137. PubMed ID: 28131047
[TBL] [Abstract][Full Text] [Related]
4. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
[TBL] [Abstract][Full Text] [Related]
5. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
[TBL] [Abstract][Full Text] [Related]
6. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry).
Kayikcioglu M; Tokgozoglu L; Yilmaz M; Kaynar L; Aktan M; Durmuş RB; Gokce C; Temizhan A; Ozcebe OI; Akyol TK; Okutan H; Sag S; Gul OO; Salcioglu Z; Yenercag M; Altunkeser BB; Kuku I; Yasar HY; Kurtoglu E; Kose MD; Demircioglu S; Pekkolay Z; Ilhan O
Atherosclerosis; 2018 Mar; 270():42-48. PubMed ID: 29407887
[TBL] [Abstract][Full Text] [Related]
7. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.
Græsdal A; Bogsrud MP; Holven KB; Nenseter MS; Narverud I; Langslet G; Brekke M; Retterstøl K; Arnesen KE; Ose L
J Clin Lipidol; 2012; 6(4):331-9. PubMed ID: 22836070
[TBL] [Abstract][Full Text] [Related]
8. Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica.
Alves AC; Alonso R; Diaz-Diaz JL; Medeiros AM; Jannes CE; Merchan A; Vasques-Cardenas NA; Cuevas A; Chacra AP; Krieger JE; Arroyo R; Arrieta F; Schreier L; Corral P; Bañares VG; Araujo MB; Bustos P; Asenjo S; Stoll M; Dell'Oca N; Reyes M; Ressia A; Campo R; Magaña-Torres MT; Metha R; Aguilar-Salinas CA; Ceballos-Macias JJ; Morales ÁJR; Mata P; Bourbon M; Santos RD
Arterioscler Thromb Vasc Biol; 2020 Oct; 40(10):2508-2515. PubMed ID: 32757650
[TBL] [Abstract][Full Text] [Related]
9. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.
Raal FJ; Santos RD
Atherosclerosis; 2012 Aug; 223(2):262-8. PubMed ID: 22398274
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey.
D'Erasmo L; Gallo A; Cefalù AB; Di Costanzo A; Saheb S; Giammanco A; Averna M; Buonaiuto A; Iannuzzo G; Fortunato G; Puja A; Montalcini T; Pavanello C; Calabresi L; Vigna GB; Bucci M; Bonomo K; Nota F; Sampietro T; Sbrana F; Suppressa P; Sabbà C; Fimiani F; Cesaro A; Calabrò P; Palmisano S; D'Addato S; Pisciotta L; Bertolini S; Bittar R; Kalmykova O; Béliard S; Carrié A; Arca M; Bruckert E
Orphanet J Rare Dis; 2021 Sep; 16(1):381. PubMed ID: 34496902
[TBL] [Abstract][Full Text] [Related]
11. High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.
Drouin-Chartier JP; Tremblay AJ; Bergeron J; Lamarche B; Couture P
Atherosclerosis; 2018 Mar; 270():26-32. PubMed ID: 29407885
[TBL] [Abstract][Full Text] [Related]
12. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
Vishwanath R; Hemphill LC
J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
[TBL] [Abstract][Full Text] [Related]
13. Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.
Raal FJ; Sjouke B; Hovingh GK; Isaac BF
Atherosclerosis; 2016 May; 248():238-44. PubMed ID: 27017151
[TBL] [Abstract][Full Text] [Related]
14. Treatment of homozygous familial hypercholesterolaemia in paediatric patients: A monocentric experience.
Buonuomo PS; Macchiaiolo M; Leone G; Valente P; Mastrogiorgio G; Gnazzo M; Rana I; Gonfiantini MV; Gagliardi MG; Romano F; Bartuli A
Eur J Prev Cardiol; 2018 Jul; 25(10):1098-1105. PubMed ID: 29785886
[TBL] [Abstract][Full Text] [Related]
15. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
[TBL] [Abstract][Full Text] [Related]
16. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.
Cuchel M; Bruckert E; Ginsberg HN; Raal FJ; Santos RD; Hegele RA; Kuivenhoven JA; Nordestgaard BG; Descamps OS; Steinhagen-Thiessen E; Tybjærg-Hansen A; Watts GF; Averna M; Boileau C; Borén J; Catapano AL; Defesche JC; Hovingh GK; Humphries SE; Kovanen PT; Masana L; Pajukanta P; Parhofer KG; Ray KK; Stalenhoef AF; Stroes E; Taskinen MR; Wiegman A; Wiklund O; Chapman MJ;
Eur Heart J; 2014 Aug; 35(32):2146-57. PubMed ID: 25053660
[TBL] [Abstract][Full Text] [Related]
17. Homozygous familial hypercholesterolemia with severe involvement of the aortic valve-A sibling-controlled case study on the efficacy of lipoprotein apheresis.
Galiano M; Hammersen J; Sauerstein K; Blessing H; Rümmele P; Purbojo A; Schöber M; Moosmann J; Raffelsbauer G; Heibges A; Klingel R
J Clin Apher; 2020 Jun; 35(3):163-171. PubMed ID: 32163632
[TBL] [Abstract][Full Text] [Related]
18. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.
Vuorio A; Tikkanen MJ; Kovanen PT
Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052
[TBL] [Abstract][Full Text] [Related]
20. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
